Benralizumab first AstraZeneca respiratory biologic to complete Phase III

17 May 2016

AstraZeneca today announced that benralizumab, a potential new medicine and anti
-eosinophil monoclonal antibody, was well tolerated and achieved the primary
endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA),
demonstrating significant reductions in the annual asthma exacerbation rate
compared to placebo.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief
Medical Officer, said: “Severe asthma affects the health and quality of life of
millions of people around the world, and exacerbations can be life threatening
for these patients. We are pleased with the top-line results from these pivotal
trials as they demonstrate the potential for benralizumab to improve outcomes
for patients with severe asthma. Benralizumab is AstraZeneca’s first respiratory
biologic and its development underscores our commitment to transform the
treatment of asthma and chronic respiratory disease with our next
generation of respiratory medicines.”

The trials evaluated the efficacy and safety of two dose regimens of
benralizumab as an add-on therapy for severe uncontrolled asthma with
eosinophilic inflammation in adults and adolescents 12 years of age and older.

In SIROCCO and CALIMA, the primary analysis population included patients on high
-dose inhaled corticosteroids (ICS) plus long-acting β2-agonist (LABA) with a
baseline blood eosinophil count ≥ 300 cells/microliter. Patients were randomised
to receive benralizumab 30mg every 4 weeks; 30mg every 4 weeks for the first
three doses followed by 30mg every 8 weeks; or placebo. The safety and
tolerability findings for benralizumab were generally consistent with those
reported in previous trials.

Mark FitzGerald, MD, director of the Centre for Heart and Lung Health at the
Vancouver Coastal Health Research Institute and Principal Investigator in the
CALIMA trial, said: “We are learning more about different sub-types of asthma,
and these trials investigate a potential new treatment to address the underlying
driver for some patients. Within the appropriate patient population, the anti
-eosinophil effect of benralizumab has the potential to deliver uniquely
-targeted treatment for patients whose asthma is driven by eosinophilic

Eosinophils are the biological effector cells that drive inflammation and
airways hyper-responsiveness in approximately 50% of asthma patients, leading to
frequent exacerbations, impaired lung function and reduced quality of life.
Benralizumab is an anti-eosinophil monoclonal antibody that depletes eosinophils
via antibody‐dependent cell-mediated cytotoxicity (ADCC), the process by which
natural killer cells are activated to target eosinophils. Benralizumab induces
direct, rapid, and near complete depletion of eosinophils in the bone marrow,
blood and target tissue. Benralizumab was developed by MedImmune, AstraZeneca’s
global biologics research and development arm.

Results from the SIROCCO and CALIMA trials will be presented at a future medical
meeting.  Regulatory submissions in the US and EU are anticipated in the second
half of 2016.

About Asthma

Asthma is a common, chronic condition in which inflammation and narrowing of the
airways may cause wheezing, breathlessness, chest tightness and coughing. Asthma
currently affects the health and day-to-day lifestyles of 315 million
individuals worldwide, and by 2020 will likely increase in numbers to as many as
400 million people.

Up to 10% of asthma cases are severe, of which approximately 40% are
uncontrolled. Severe, uncontrolled asthma has eight times higher risk of
mortality than severe asthma. Uncontrolled asthma can lead to a dependence on
oral corticosteroid (OCS). Systemic steroid exposure leads to serious and
irreversible adverse effects, including osteoporosis, anxiety, depression,
weight gain, glaucoma and diabetes. There is also a significant physical and
socio-economic burden of asthma with severe patients accounting for 50% of
asthma-related costs.

About the WINDWARD Programme
SIROCCO and CALIMA are both part of the comprehensive WINDWARD programme in
asthma (comprised of six Phase III trials in 3,068 patients and 798 sites,
across 26 countries), the largest Phase III development programme for a biologic
in respiratory disease.

The two registrational trials, SIROCCO and CALIMA, are randomised, double-blind,
parallel group, placebo-controlled trials designed to evaluate the efficacy and
safety of a fixed 30 mg dose of benralizumab administered subcutaneously in
patients with a history of asthma exacerbations and uncontrolled asthma
receiving ICS/LABA with or without OCS and additional asthma controllers.

A total of 2,511 patients (1,205 in SIROCCO and 1,306 in CALIMA) were randomised
globally and received benralizumab 30mg every 4 weeks; 30mg every 4 weeks for
the first three doses followed by 30mg every 8 weeks; or placebo.

In addition to WINDWARD, the Phase III VOYAGER programme is currently underway,
evaluating benralizumab in patients with severe chronic obstructive pulmonary
disease (COPD).

About Benralizumab
Benralizumab is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa
Hakko Kirin Co., Ltd. Under the exclusive license agreement, Kyowa Hakko
Kirin/BioWa have exclusive development and commercialisation rights for
benralizumab in Japan and certain countries in Asia. AstraZeneca has exclusive
rights for benralizumab in all other countries including the US and Europe.
BioWa is eligible to milestone payments and royalties from AstraZeneca related
to the development and commercialisation of benralizumab in those countries.

In July 2015 AstraZeneca entered an agreement with Kyowa Hakko Kirin Co. Ltd.
(Kyowa Hakko Kirin) for an exclusive option to commercialise benralizumab for
asthma and COPD in Japan. Under the terms of the agreement, AstraZeneca paid
Kyowa Hakko Kirin a $45 million up-front option fee and will make subsequent
payments for regulatory filing, approval and commercial milestones, and sales
royalties. Kyowa Hakko Kirin will continue to be responsible for the research
and development of benralizumab in Japan. On exercising the option, AstraZeneca
will be responsible for all sales and marketing in asthma and COPD in Japan.
Kyowa Hakko Kirin will retain the rights to participate in certain commercial
activities alongside AstraZeneca.

About Respiratory, Inflammation and Autoimmunity
Respiratory, Inflammation and Autoimmunity (RIA) is one of AstraZeneca’s main
therapy areas, and we have a growing portfolio of medicines that reached more
than 17 million patients in 2015. Our strong pipeline has the potential to
deliver up to seven launches between 2016 and 2020. In respiratory disease, our
aim is to transform asthma and COPD treatment through inhaled combinations at
the core of care, biologics for the unmet needs of specific patient populations,
and scientific advancements in disease modification. We are building on a 40
-year heritage in respiratory disease, and our capability in inhalation
technology spans both pressurised metered-dose inhalers (pMDIs) and dry powder
inhalers (DPIs), as well as our unique Co-SuspensionTM Technology.

In Inflammation and Autoimmunity, our aim is to develop innovative therapies for
the treatment of autoimmune and rheumatoid diseases, with a lead programme in
systemic lupus erythematosus. Across respiratory, inflammation and autoimmune
diseases, our research is focused on four key biological pathways: eosinophilic
disease, Th2-driven disease, epithelial-driven pathobiology, and autoimmunity.

About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a
global, innovation-driven biopharmaceutical business that focuses on the
discovery, development and commercialization of small molecule and biologic
prescription medicines. MedImmune is pioneering innovative research and
exploring novel pathways across key therapeutic areas, including respiratory,
inflammation and autoimmunity; cardiovascular and metabolic disease; oncology;
neuroscience; and infection and vaccines. The MedImmune headquarters is located
in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with
additional sites in Cambridge, UK and Mountain View, CA. For more information,
please visit

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas –
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology – as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit:


|Media Enquiries | |
|Neil Burrows |UK/Global |+44 7842 350541
|Vanessa Rhodes |UK/Global |+44 7880 400690
|Karen Birmingham |UK/Global |+44 7818 524012
|Jacob Lund |Sweden |+46 8 553 260 20
|Michele Meixell |US |+1 302 885 2677
|Investor Enquiries | |
|UK | |
|Thomas Kudsk Larsen |+44 7818 524185 |
|Eugenia Litz |RIA |+44 7884 735627
|Nick Stone |CVMD, RIA |+44 7717 618834
|Henry WheelerCraig Marks|OncologyFinance |+44 7788 354619+44 7881
|Christer Gruvris |ING, Consensus Forecasts|+44 7827 836825
|US | |
|Lindsey Trickett |Oncology, ING |+1 240 543 7970
|Mitch Chan |Oncology |+1 240 477 3771
|Dial / Toll-Free | |+1 866 381 7277

Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and
Metabolic Disease, ING – Infection, Neuroscience and Gastrointestinal


17 May 2016